fool.com·Apr 16, 2026
AbbVie's stock reached a record high of $238.71 on October 1, 2025, but has since declined by about 13%, presenting a potential buying opportunity for long-term investors, especially given the company's strong performance driven by its new immunology drugs, Skyrizi and Rinvoq.
AbbVie's recent 13% stock pullback, following a record high, presents a potential buying opportunity for long-term investors. The pullback comes despite the company's successful transition from its former blockbuster, Humira, to new revenue drivers, Skyrizi and Rinvoq, suggesting resilience and growth potential in its immunology portfolio. This could be a strategic moment to buy into AbbVie for those focused on long-term gains.